Biomea Fusion

Biomea Fusion company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are a biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in in regulating the growth of beta cells in the pancreas as well as oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop treatments against other high-value metabolic diseases and oncogenic drivers of cancer. We entered the clinic with our second development candidate, BMF-500, a covalent inhibitor of FLT3 and are studying BMF-500 in acute leukemia patients. We also announced our third development candidate, an oral, small molecule GLP-1 receptor agonist in obesity. All our molecules, BMF-219, BMF-500, and our GLP-1 receptor agonist were developed in-house by the Biomea team. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure. The name biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.” At Biomea Fusion, we develop medicines to improve the life of the individual. Visit us at biomeafusion.com

Company Details

Employees
77
Founded
-
Address
1599 Industrial Rd, San Carlos,california 94070,united States
Phone
(650) 980-9099
Email
in****@****ion.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Carlos, California
Looking for a particular Biomea Fusion employee's phone or email?

Biomea Fusion Questions

News

Biomea Fusion Announces First Patient Dosed in Phase I - GlobeNewswire

Biomea Fusion Announces First Patient Dosed in Phase I GlobeNewswire

1.8% HbA1c reduction sustained at Week 52 — Biomea Fusion's icovamenib shows durable benefit - Stock Titan

1.8% HbA1c reduction sustained at Week 52 — Biomea Fusion's icovamenib shows durable benefit Stock Titan

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series - GlobeNewswire

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series GlobeNewswire

Biomea Fusion Appoints Julianne Averill to its Board of Directors - Yahoo Finance

Biomea Fusion Appoints Julianne Averill to its Board of Directors Yahoo Finance

Biomea Fusion, Inc. Implements Strategic Realignment to Focus on Core Diabetes Programs and Optimize Cash Runway - Nasdaq

Biomea Fusion, Inc. Implements Strategic Realignment to Focus on Core Diabetes Programs and Optimize Cash Runway Nasdaq

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) - Yahoo Finance

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) Yahoo Finance

Biomea Fusion Announces Pricing of Public Offering of Securities - GlobeNewswire

Biomea Fusion Announces Pricing of Public Offering of Securities GlobeNewswire

Biomea Fusion Announces Positive 52-Week Results from Phase - GlobeNewswire

Biomea Fusion Announces Positive 52-Week Results from Phase GlobeNewswire

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights GlobeNewswire

Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire

Biomea Fusion Announces Proposed Public Offering of Securities GlobeNewswire

Biomea Fusion Announces Pricing of Public Offering of Securities - GlobeNewswire

Biomea Fusion Announces Pricing of Public Offering of Securities GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates - GlobeNewswire

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates GlobeNewswire

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights GlobeNewswire

Biomea Fusion Announces Leadership Transition - GlobeNewswire

Biomea Fusion Announces Leadership Transition GlobeNewswire

Biomea Fusion to Become a Diabetes & Obesity Medicines Company - GlobeNewswire

Biomea Fusion to Become a Diabetes & Obesity Medicines Company GlobeNewswire

Biomea Fusion Announces Positive Topline Results from - GlobeNewswire

Biomea Fusion Announces Positive Topline Results from GlobeNewswire

48,000 Stock Options: Biomea Fusion Makes Key Inducement Grant Under 2023 Equity Plan - Stock Titan

48,000 Stock Options: Biomea Fusion Makes Key Inducement Grant Under 2023 Equity Plan Stock Titan

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 - GlobeNewswire

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 GlobeNewswire

Biomea Fusion’s BMF-500 Selected for Poster Presentation at - GlobeNewswire

Biomea Fusion’s BMF-500 Selected for Poster Presentation at GlobeNewswire

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - Yahoo Finance

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate Yahoo Finance

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights GlobeNewswire

Diabetes Drug Developer Biomea Fusion Raises $40M in Strategic Public Offering with Warrant Sweetener - Stock Titan

Diabetes Drug Developer Biomea Fusion Raises $40M in Strategic Public Offering with Warrant Sweetener Stock Titan

Biomea Fusion Slashes Workforce by 35%, Shifts Focus to $200B Diabetes Market Opportunity - Stock Titan

Biomea Fusion Slashes Workforce by 35%, Shifts Focus to $200B Diabetes Market Opportunity Stock Titan

Biomea Fusion Grants 30,000 Stock Options to New Employee Under Inducement Plan - Stock Titan

Biomea Fusion Grants 30,000 Stock Options to New Employee Under Inducement Plan Stock Titan

Biomea Fusion Expands Team with Strategic Equity Compensation Package - Stock Titan

Biomea Fusion Expands Team with Strategic Equity Compensation Package Stock Titan

Diabetes Drug Trial Shows 55% C-Peptide Boost, Enhanced GLP-1 Results | BMEA Stock News - Stock Titan

Diabetes Drug Trial Shows 55% C-Peptide Boost, Enhanced GLP-1 Results | BMEA Stock News Stock Titan

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort - Yahoo Finance

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort Yahoo Finance

Treatment With Novel KRAS Inhibitor Commences in Phase 1/1B Study, COVALENT-10 - Targeted Oncology

Treatment With Novel KRAS Inhibitor Commences in Phase 1/1B Study, COVALENT-10 Targeted Oncology

Biomea Fusion Presents at the 2022 ASH Annual Meeting - GlobeNewswire

Biomea Fusion Presents at the 2022 ASH Annual Meeting GlobeNewswire

Biomea Announces Pricing of Initial Public Offering - GlobeNewswire

Biomea Announces Pricing of Initial Public Offering GlobeNewswire

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant